Search
anti-hyperlipidemic agent
Notes:
- combination of low-dose statin plus either a bile acid sequestrant or ezetimibe reduces LDL cholesterol more than high-dose statin monotherapy [1]
- long-term clinical benefits uncertain
Interactions
drug adverse effects of anti-hyperlipidemic agents
Related
hypercholesterolemia
hyperlipoproteinemia (HLP)
hypertriglyceridemia
lipid panel (fasting lipid panel, FLP)
Specific
bile acid sequestrant
cholesterol absorption inhibitor
cholesteryl ester transfer protein (CETP) inhibitor
combination antihyperlipidemic agent/therapy
dextrothyroxine (Cholixin)
evacetrapib
evinacumab-dgnb (Evkeeza)
fibrate
HMG CoA reductase inhibitor (statin)
lepodisiran
lomitapide (Juxtapid)
LY295427
mipomersen (Kynamro)
nicotinic acid (niacin, vitamin B3, Niaspan)
oxandrolone (Oxandrin)
PCSK9 inhibitor (ALN-PCS)
policosanol
probucol (Lorelco)
rimonabant (Acomplia, Zimulti)
General
pharmaceutical agent
References
- Gudzune KA, Monroe AK, Sharma R et al
Effectiveness of Combination Therapy With Statin and Another
Lipid-Modifying Agent Compared With Intensified Statin
Monotherapy: A Systematic Review.
Ann Intern Med. Published online 11 February 2014
PMID: 24514899
http://annals.org/article.aspx?articleid=1828554